Evaxion A/S

Evaxion A/S, a clinical-stage TechBio company, has been awarded the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology™ platform. This prestigious award serves as a strong external validation of the platform's innovative use of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases. This marks the second recognition from the Galien Prix Foundation in less than a year, highlighting the platform's significant scientific development and tangible impact on human health.

Evaxion A/S has been awarded the prestigious 2026 Prix Galien UK Award for Best digital health solution, recognizing its AI-Immunology™ platform. This marks the second time in less than a year that Evaxion has received an award from the Galien Prix Foundation, underscoring the external validation of its AI-Immunology™ platform. The platform leverages artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

Evaxion A/S announced new preclinical data for its off-the-shelf therapeutic vaccine candidate, EVX-04, for acute myeloid leukemia (AML). The data shows successful expression and secretion of EVX-04 in human cells, leading to immune recognition and activation. The vaccine antigens demonstrated the ability to drive specific immune responses and induce targeted cell-killing in preclinical models. Evaxion plans to present these findings at the European Hematology Association (EHA) 2026 Congress.

Evaxion A/S announced new positive preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), developed using its AI-Immunology™ platform. The data demonstrates EVX-04's successful expression and secretion in human cells, enabling immune recognition and activation. It also showed that the vaccine antigens drive specific immune responses and induce targeted cell-killing, highlighting its potential as an effective cancer vaccine. The company is preparing for regulatory filing for clinical testing, and the data will be presented at the European Hematology Association (EHA) 2026 Congress.

Evaxion A/S announced it will present new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), at the European Hematology Association (EHA) 2026 Congress in June. The data will focus on the functional characterization of EVX-04, an AI-designed vaccine targeting endogenous retroviral antigens. This presentation signifies a crucial step towards clinical testing, with the company planning to submit a clinical trial application in the second half of 2026.

Evaxion A/S provided a business update and announced its first quarter 2026 financial results, reporting a net loss of $3.6 million, an increase from $1.6 million in Q1 2025, primarily due to a non-recurring financial income in the prior year. The company highlighted significant progress, including new data demonstrating 86% vaccine target recognition by its AI-Immunology platform in personalized cancer vaccine EVX-01, and the successful completion of the one-year extension of its EVX-01 phase 2 trial. Evaxion also reported $18.4 million in cash and cash equivalents as of March 31, 2026, maintaining its cash runway into the second half of 2027, and announced key organizational optimizations.

Evaxion A/S, a clinical-stage TechBio company, announced it will provide a business update and report its first quarter 2026 financial results on Thursday, May 7, 2026, before the Nasdaq CM opens. The company's Executive Management will host a conference call and webcast on the same day at 14:30 CET/08:30 EST to present the update and results, and to answer questions. Registration is required for the conference call, and a webcast recording will be available online.

Evaxion A/S, a clinical-stage TechBio company, announced the promotion of Birgitte Rønø to the combined position of Chief Scientific and Chief Operating Officer. This strategic leadership change aims to leverage Rønø's expertise across both scientific development and operational management.

Evaxion A/S announced that Birgitte Rønø, Chief Scientific Officer (CSO), will assume the dual role of CSO and Chief Operating Officer (COO). This expansion of her remit reflects an organizational alignment aimed at maximizing external engagement and strategy execution, particularly to enhance the visibility of Evaxion's AI-Immunology™ platform with partners and investors. The change also recognizes Dr. Rønø's extensive contributions to the company's internal operations. The management team remains composed of Helen Tayton-Martin (CEO), Birgitte Rønø (CSO & COO), Thomas Schmidt (CFO), and Andreas Mattsson (Chief AI Officer).

Evaxion A/S announced new Phase 2 data for its personalized cancer vaccine EVX-01, demonstrating an 86% success rate in vaccine targets triggering a tumor-specific immune response. This high rate, significantly above other reported methods, validates Evaxion's AI-Immunology™ platform. The data also showed durable two-year vaccine-specific immune responses and a positive correlation between AI-prediction scores and immune response magnitude, reinforcing the platform's predictive power and the vaccine's potential for strong anti-tumor effects.